NCT06279195View on ClinicalTrials.gov

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2024

Primary Completion Date

November 2, 2025

Study Completion Date

November 2, 2025

Conditions
Pelvic Pain
Interventions
DRUG

Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet

All participants will be instructed to take REL-CT.

Trial Locations (1)

60201

NorthShore University HealthSystem, Evanston

Sponsors

Lead Sponsor

Endeavor Health

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Endeavor Health

OTHER